Skin Cancer/Melanoma

After a previous diagnosis of skin cancer, patients are more likely to develop skin cancer lesions on the body. An expert gives helpful tips on what to look for and how to look for lesions to catch them early.

Patients with basal cell or cutaneous squamous cell carcinoma tend to have good outcomes when the disease is caught early. For those in later stages, new treatments bring hope and better prognoses.

Anna C. Pavlick, DO, provides an overview of hedgehog inhibitors, a first-line treatment option for patients diagnosed with locally advanced basal cell carcinoma (laBCC).

A discussion about multidisciplinary management of locally advanced basal cell carcinoma (laBCC) and how dermatologists and medical oncologists collaborate within the care of a patient.

An expert discusses features of a skin lesion that would prompt a skin biopsy in the diagnosis of locally advanced basal cell carcinoma (laBCC).

Anna C. Pavlick, D.O., provides an overview of locally advanced basal cell carcinoma (laBCC) that includes the different risk factors and clinical presentations.

Learn the differences between sunscreen types and what to look for.

View the full CURE Educated Patient Skin Cancer Summit on demand.

Even with newer technologies such as mRNA, experts predict it will be a few years before another cancer vaccine is approved.

As we all head outdoors to enjoy the warmer weather, The Skin Cancer Foundation would like to remind everyone how to use sunscreen safely and effectively as part of a complete sun protection strategy.

More than six years of follow-up data show that Opdivo alone, or in combination with Yervoy, continued to induce long-term survival benefits compared to Yervoy alone in patients with previously untreated advanced skin cancer.

Lifileucel with Keytruda may lead to an improved overall response rate of 86% for patients with advanced melanoma who were pre-checkpoint inhibitor naïve compared with those treated with Keytruda alone.

From a cancer survivor who cleans up trash and turns it into artwork to the inaugural National Black Family Cancer Awareness week, here’s what’s happening in the cancer landscape this week.

“Summer finds many of us outdoors and during that time, it’s important to protect our skin from the dangerous rays of the sun,” writes one breast cancer survivor. Learn more about how to use sunscreen, protect your skin and avoid skin cancer.

The use of Opdivo combined with the novel therapy relatlimab resulted in a significant improvement of progression-free survival compared to treatment with Opdivo, alone, in patients with previously untreated, unresectable or metastatic melanoma.

In honor of Skin Cancer Awareness Month, CURE® compiled some recent news and updates from this field that patients, survivors and caregivers may have missed.

A melanoma survivor pens a poem about his cancer journey, losing his wife to melanoma and how he lives his life after these experiences.

Patients with melanoma treated with Keytruda had improved recurrence-free survival without an effect on their quality of life.

When caught and treated early, skin cancer is highly curable. When allowed to progress, however, it can cause disfigurement and even death.

Which story – of hope or fear – is the best experience to relate to help another?

In patients with resected high-risk stage 3 cutaneous melanoma, distant metastasis-free survival at 3.5 years was 65.3% in patients treated with Keytruda compared with 49.4% in those treated with placebo, which was also consistent in patients with PD-L1-positive tumors.

Keytruda demonstrated clinical benefit for patients with recurrent and metastatic disease, according to an expert.

Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.

Chronic immune-related adverse events from anti-PD-1 therapy occur in many patients with advanced melanoma, but shouldn’t deter them from seeking treatment that can provide long-term survival, according to an expert from Vanderbilt University Medical Center.

FDA approval of immunotherapies and BRAF/MEK inhibitors may have impacted overall survival, with a change from seven months between 2010 and 2014 to 13 months between 2015 and 2019.